Alfredo E. Rodriguez, MD, PhD

Oral Rapamycin in the Treatment of Diffuse Proliferative In-Stent Restenosis in a Patient with Small Reference Vessel

08/01/2008

Case Report. A 63-year-old man was admitted to our hospital due to recent onset chest pain with radiation to the left arm, which was precipitated by minimum efforts and relieved by rest. He was evaluated at the coronary care unit and treated...

Case Report. A 63-year-old man...

08/01/2008

Journal of Invasive Cardiology

Pilot Study of Oral Rapamycin to Prevent Restenosis in Patients Undergoing Coronary Stent Therapy: Argentina Single-Center Study

08/01/2008

Miguel Russo , MD;

John A. Ambrose , MD;

Claudio Llaurado , BS;

Carlos Fernandez-Pereira , MD;

Alfredo E. Rodriguez , MD, PhD;

Renu Virmani , MD, PhD;

Maximo Rodriguez Alemparte , MD;

Cesar F. Vigo , MD;

Observational and randomized studies recently showed that sirolimus-coated stents were associated with a lower rate of restenosis than bare stents.1–3 Although the restenosis rate was lower, coated stents have a significantly higher cost than...

Observational and randomized...

08/01/2008

Journal of Invasive Cardiology

Commentary

IAGS Discussion ‚Äì Supporting Patients in Shock

08/01/2008

Luis de la Fuente ;

Howard A. Cohen , MD;

Gian Feltrin ;

Tom J. Linnemeier , MD;

Alfredo E. Rodriguez , MD, PhD;

James P. Zidar , MD;

Paul A. Overlie , MD, FACC, FACP;

Jeffrey Werner , MD;

Fayaz Shawl , MD;

Kirk N. Garratt , MD, MSc;

The High Mortality Among Patients in Cardiogenic Shock “LV or RV Infarcts:” What Have We Learned and Have We Made a Difference? In this symposium, we will revisit the treatment of cardiogenic shock complicating acute myocardial infarction...

The High Mortality Among...

08/01/2008

Journal of Invasive Cardiology

Commentary

IAGS discussion ‚Äì Supporting Patients in Shock (Part ii)

08/01/2008

Jeffrey Werner , MD;

Howard A. Cohen , MD;

Luis de la Fuente ;

Gian Feltrin ;

Alfredo E. Rodriguez , MD, PhD;

Tom J. Linnemeier , MD;

James P. Zidar , MD;

Paul A. Overlie , MD, FACC, FACP;

Fayaz Shawl , MD;

Kirk N. Garratt , MD, MSc;

Part ii Continuation of discussion Supporting Patients in Shock Jeff Werner: I have a question for Dr. Shawl. I believe you said that you think patients should be completely revascularized during acute infarction using angioplasty and...

Part ii Continuation of...

08/01/2008

Journal of Invasive Cardiology

Feature

IAGS Proceedings - <br />
Troubling Lesion Subsets: Bifurcation Disease

08/01/2008

Brian O'Murchu , MD;

Howard A. Cohen , MD;

Hal Whitworth ;

Jeffrey Werner , MD;

Michael Cowley , MD;

Alfredo E. Rodriguez , MD, PhD;

James P. Zidar , MD;

Raoul Bonan , MD;

Kirk N. Garratt , MD, MSc;

Max Amor , MD;

Tom J. Linnemeier , MD;

Christopher U. Cates , MD;

Moderator: Kirk Garratt Panel Members: Tom Linnemeier, Brian O’Murchu, Jeffrey Werner Tom Linnemeier: The best treatment option today for a true LAD diagonal bifurcation lesion is to place a stent in the LAD and dilate through the...

Moderator: Kirk Garratt Panel...

08/01/2008

Journal of Invasive Cardiology

Case Report

Late Stent Thrombosis Mimicking Focal Restenosis after Sirolimus Stent Implantation: Angiographic and Intravascular Ultrasound A

08/01/2008

Gaston A. Alfredo Rodriguez-Granillo , MD;

Carlos Fernandez-Pereira , MD;

Alfredo E. Rodriguez , MD, PhD;

Since the introduction of drug-eluting stents (DES) during interventional procedures, several randomized studies have demonstrated a significant reduction in coronary restenosis and target vessel revascularizations.1–4 However, despite the...

Since the introduction of...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

New Coating Stent Design for Patients with High-Risk Coronary Lesions for Thrombotic Events: (Full title below)

08/17/2009

Gilberto Perez , MD;

Alfredo M. Rodriguez-Granillo , BS;

Juan Mieres , MD;

Claudio Llaurado , BS;

Bibiana Rubilar , MD;

Gustavo Risau , MD;

Carlos Fernandez-Pereira , MD;

Alfredo E. Rodriguez , MD, PhD;

ABSTRACT: Background. Semisynthetic coating of the Camouflage bare-metal stent (BMS) (Eucatech AG, Rheinfelden, Germany) mimics luminal endothelial cell glycocalix, potentially preventing the activation of the coagulation system. Purpose. We...

ABSTRACT: Background....

08/17/2009

Journal of Invasive Cardiology

IAGS (International Andreas Gruentzig Society) Proceedings

Drug-Eluting Stents: Current Limitations

08/01/2008

Jamey Jacobs ;

Tim A. Fischell , MD, FACC, FSCAI;

Jorge A. Belardi , MD, PhD;

Christopher U. Cates , MD;

Alfredo E. Rodriguez , MD, PhD;

Gregory Braden , MD;

Mike Cowley , MD;

David Sperling , MD;

Robert Fischell , MD;

Mike Cowley: Let’s begin with discussing case selection. Which patients should receive drug-eluting stents (DES)? Should they only receive one stent? Should we reserve DES for a select patient population? What should the approach be for...

Mike Cowley: Let’s begin with...

08/01/2008

Journal of Invasive Cardiology